The Power of Blood - Transforming Cancer Care with Liquid Biopsy

Guardant Health is dedicated to helping patients at all stages of cancer live longer and healthier, through the power of liquid biopsy and the genomic data it unlocks.
For advanced cancer patients today, our Guardant360 CDx test unlocks genomic signals from tumor DNA fragments shed into the blood, revealing critical information to help identify the right precision medicine. With every blood sample sequenced, real-world evidence is being generated, fueling product enhancements and accelerating progress toward the early detection of cancer. Through our LUNAR-1 program, we are applying multi-dimensional analysis to screen for residual or recurrent disease in cancer survivors and identifying early stage patients who may be cured by new therapies in development. With our LUNAR-2 program, we are poised to delve even deeper. We've initiated the ten thousand patient ECLIPSE trial, for the early detection of colorectal cancer in asymptomatic patients -- the backbone of our early cancer detection program.
Each day, Guardant Health is proving that blood can change the trajectory of the fight against cancer. Learn more at guardanthealth.com.